Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Renalytix logo — Transforming kidney disease care with one simple blood test.

Renalytix

Transforming kidney disease care with one simple blood test.

Founded 2018 United States New York, United States 54 employees IPO Total: $82.70M AI, Biotechnology +2

General Information

Company Name Renalytix
Founded Year 2018
Location United States New York, United States
Founders / Decision Makers
Team member Team member
Employees 54
Industries AI, Biotechnology, Health Care +1
Funding Stage IPO
Business Model B2B, D2C, SaaS
Revenue Model Service Fee, Usage Based, Data Monetization
Social

BounceWatch is an independent company data service, not affiliated with Renalytix. To contact Renalytix, visit renalytix.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Renalytix compare?

A PDF of Renalytix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Renalytix soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Renalytix

Renalytix, founded in 2018, is pioneering the field of bioprognosis™ to revolutionize kidney disease care. With its headquarters in the United States, the company is at the forefront of AI, Biotechnology, Health Care, and Medical Devices industries.

The company’s unique proposition lies in its ability to deliver early-stage and progression risk assessments for kidney health, using a proprietary solution that simplifies diagnosis through a single blood test. Their slogan, "Transforming kidney disease care with one simple blood test," encapsulates this innovation.

Renalytix has already captured significant attention on both the LSE and NASDAQ. Its latest financial milestone was a Post IPO Equity investment on 01 February 2026, backed by First Equity Limited. This positions the company as a compelling opportunity for investors seeking cutting-edge advancements in medical diagnostics and therapeutics. Such strategic investments and innovations secure its standing as a global leader, committed to eradicating kidney disease.™

Business keywords: bioprognosis, kidney health, early-stage risk assessment, AI-enabled diagnostics, clinical care improvement, patient stratification, predictive biomarkers, genomic data analysis, health data utilization, clinical utility enhancement, chronic disease management, AI in healthcare

Services & Products

KidneyIntelX Testing Technology
Risk Prediction for CKD Progression
Prognostic Blood Testing

Target Customers

Healthcare Providers Clinicians Primary Care Providers Nephrologists Cardiologists Endocrinologists Healthcare Institutions

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity Undisclosed 1
First Equity Limited
01 Feb 2026
Post-IPO Equity £5.20M -
01 Sep 2025
IPO £11.80M -
01 Oct 2024
Post-IPO Equity $1.00M 1
DB Capital Partners
01 Apr 2024
Grant £16.90M -
01 Feb 2023
Post-IPO Equity $8.80M -
01 Apr 2022
Post-IPO Equity £14.00M -
01 Jul 2019
IPO £25.00M -
01 Nov 2018

Latest News

View All
JPM 2022: Renalytix plots de novo FDA nod for kidney disease AI, expands into drug response monitori... — Fiercebiotech.com
JPM 2022: Renalytix plots de novo FDA nod for kidney disease AI, expands into drug response monitoring
Fiercebiotech.com Nov 23, 2025
Renalytix Announces Fundraise to Support US Expansion — Tipranks.com
Renalytix Announces Fundraise to Support US Expansion
Tipranks.com Sep 22, 2025
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kid... — Wjhl.com
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease
Wjhl.com Sep 15, 2025
Renalytix shares surge 45% on Tempus collaboration — Proactiveinvestors.co.uk
Renalytix shares surge 45% on Tempus collaboration
Proactiveinvestors.co.uk Sep 15, 2025
15M Diabetic Kidney Patients: Renalytix and Tempus Launch Groundbreaking AI Testing Partnership — Stocktitan.net
15M Diabetic Kidney Patients: Renalytix and Tempus Launch Groundbreaking AI Testing Partnership
Stocktitan.net Sep 15, 2025
REG - Renalytix PLC - Tempus AI Inc, collaboration agreement — Tradingview.com
REG - Renalytix PLC - Tempus AI Inc, collaboration agreement
Tradingview.com Sep 14, 2025

Renalytix Alternatives & Competitors

View All Alternatives
Renalytix vs
Carenostics
Carenostics United States

Addressing the underdiagnosis, undertreatment, and health inequities of chronic disease using AI and...

Seed
13 employees
AI, Biotechnology
Compare Renalytix vs Carenostics
Renalytix vs
UpDoc
UpDoc United States

Pioneering Remote Patient Intervention | Augmenting Clinical Care with AI

Seed
16 employees
AI, Health Care
Compare Renalytix vs UpDoc
Renalytix vs
dehaze
dehaze Germany

Detecting chronic diseases before symptoms occur.

Seed
15 employees
AI, Health Care
View all alternatives

FAQ About Renalytix

Transforming kidney disease care with one simple blood test.
Renalytix was founded in 2018.
Renalytix is headquartered in New York, United States.
Renalytix operates in AI, Biotechnology, Health Care and Medical Devices. Its work centres on bioprognosis, kidney health, early-stage risk assessment and AI-enabled diagnostics. Its customers include Healthcare Providers, Clinicians and Primary Care Providers.
Renalytix has a B2B, D2C and SaaS business model. Its revenue comes from Service Fee, Usage Based and Data Monetization.
Renalytix has approximately 54 employees.
Renalytix has completed 8 funding rounds, raising a total of $82.70M. The latest funding stage is IPO.
Renalytix offers: KidneyIntelX Testing Technology, Risk Prediction for CKD Progression, Prognostic Blood Testing.
Top alternatives and competitors to Renalytix include Carenostics, UpDoc, dehaze, PIPRA, Delphyr. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Renalytix and Carenostics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Renalytix, https://bouncewatch.com/company/renalytix-ai, updated 6 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout